Navigation Links
FDA Performs Inspection of Impax's Hayward Facility

HAYWARD, Calif., Aug. 4, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) performed a re-inspection of the Company's Hayward, California manufacturing facility from June 16 to July 31, 2014. At the conclusion of the inspection, the FDA issued a Form 483 with seven inspectional observations, two of which are designated as repeat observations.

The FDA did not provide any status or classification to these observations and, pursuant to its established regulatory process, will defer classification until it has reviewed the Company's response to the inspection. The Company is working diligently to address FDA's observations and will respond to them within 15 days of receipt of the Form 483.

"Addressing these latest observations and advancing our quality improvement initiatives are our top priorities," said Fred Wilkinson, president and chief executive officer of Impax Laboratories. "Our dedicated teams are focused on creating a world class quality organization."

"While the past week has been challenging, I remain enthusiastic about Impax's future and the opportunities ahead of us. We have a track record of development and commercialization success, and a strong pipeline of pending products. In addition, we have the financial resources and balance sheet to create new revenue sources through internal and external development, while pursuing strategic and accretive M&A opportunities."

The Company has provided a redacted version of the Form 483 as an exhibit in a Current Report on Form 8-K filed with the SEC concurrently with the issuance of this press release.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance, or achievements to differ significantly from the results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: fluctuations in revenues and operating income; the Company's ability to promptly correct the issues raised in the warning letter and Form 483 observations received from the FDA; the Company's ability to successfully develop and commercialize pharmaceutical products in a timely manner; reductions or loss of business with any significant customer; the impact of consolidation of the Company's customer base; the impact of competition; the substantial portion of our total revenues derived from sales of a limited number of products; the Company's ability to sustain profitability and positive cash flows; any delays or unanticipated expenses in connection with the operation of the Company's manufacturing facilities; the effect of foreign economic, political, legal, and other risks on the Company's operations abroad; the uncertainty of patent litigation and other legal proceedings; the increased government scrutiny on the Company's agreements with brand pharmaceutical companies; product development risks and the difficulty of predicting FDA filings and approvals; consumer acceptance and demand for new pharmaceutical products; the impact of market perceptions of the Company and the safety and quality of the Company's products; the Company's determinations to discontinue the manufacture and distribution of certain products; the Company's ability to achieve returns on its investments in research and development activities; the Company's inexperience in conducting clinical trials and submitting new drug applications; the Company's ability to successfully conduct clinical trials; the Company's reliance on third parties to conduct clinical trials and testing; the Company's lack of a license partner for commercialization of IPX066 outside of the United States; impact of illegal distribution and sale by third parties of counterfeits or stolen products; the availability of raw materials and impact of interruptions in the Company's supply chain; the Company's policies regarding returns, allowances and chargebacks; the use of controlled substances in the Company's products; the effect of current economic conditions on our industry, business, results of operations and financial condition; disruptions or failures in the Company's information technology systems and network infrastructure; the Company's reliance on alliance and collaboration agreements; the Company's reliance on licenses to proprietary technologies; the Company's dependence on certain employees; the Company's ability to comply with legal and regulatory requirements governing the healthcare industry; the regulatory environment; the Company's ability to protect its intellectual property; exposure to product liability claims; risks relating to goodwill and intangibles; changes in tax regulations; the Company's ability to manage growth, including through potential acquisitions; the restrictions imposed by the Company's credit facility; uncertainties involved in the preparation of the Company's financial statements; the Company's ability to maintain an effective system of internal control over financial reporting; the effect of terrorist attacks on the Company's business; the location of the Company's manufacturing and research and development facilities near earthquake fault lines; expansion of social media platforms; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Company Contact:                   
Mark Donohue                                  
Investor Relations and Corporate Communications                                
(215) 558-4526                                                 

SOURCE Impax Laboratories, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patients Bedside In Less Than An Hour
2. UCLA Performs First Breathing Lung Transplant In United States
3. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
4. Only Podiatric Surgeon In S. Florida That Performs In-Office Ultrasound Imaging On Foot & Ankle Problems Saving Patients Over $1,000 In MRI Expenses & Extra Trip To Hospital
5. Molecular Imaging Services, Inc. Performs First Rubidium-82 Cardiac PET Scan In Delaware
6. Conroe Physician Performs Laser Tattoo Removal with Astanza Duality Technology at Vanishing Ink MD
7. Henry Ford Hospital Performs First Minimally Invasive Laser Brain Surgeries in Michigan
8. Harrisburg-based Cardiovascular Institute Performs First MitraClip Procedure in Pennsylvania
9. Keck Medicine of USC performs worlds 1st implant after FDA approval for groundbreaking epilepsy treatment
10. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
11. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: ... of chronic pain, announced today that the company will present ... held December 1-3 at the Luxe Sunset Boulevard Hotel in ... , CEO of Relmada Therapeutics, will present on Thursday, December ... . Please register at least 10 minutes ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- ... the company’s growing product line of food safety and seafood fraud prevention tools. ... nerka) – allow InstantLabs to offer fast, reliable species identification for the four ...
(Date:12/1/2015)... ... 01, 2015 , ... It’s official: Tattoo taboo is a thing of the ... among Millennials (a whopping one in three aged 18 to 25 is inked). As ... with their ink. In fact, RealSelf , the world’s largest community for learning ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus ... imaging results enhancements at the Radiological Society of North America (RSNA) 2015 annual ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, ... fixed price per sprint agile development contract to support the National Geospatial-Intelligence Agency's ... years, provides software engineering, infrastructure, as well as operations and sustainment support to ...
Breaking Medicine News(10 mins):